Hemogenyx Pharmaceuticals
Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Hemogenyx Pharmaceuticals, Biotechnology company, 760 Parkside Avenue, New York, NY.
Hemogenyx Pharmaceuticals is a biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. HemoGenyx Pharmaceuticals PLC (LSE: HEMO) is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of n
04/25/2024
Hemogenyx Pharmaceuticals reflects on ‘vital year’, eyes number of strategies to advance its clinical opportunities Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) chair Marc Feldmann, in the company’s final results statement, described the year as a “period was a...
03/13/2024
Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T program Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical...
06/20/2023
🌟 Witness the cutting-edge innovation of as they revolutionize drug development!Their groundbreaking methods and technologies are saving lives by creating new and effective medicines. Join the journey of scientific discovery and hope! 🚀
https://lnkd.in/eBCnyMdv
One of America's Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director
https://www.biospace.com/article/releases/hemogenyx-pharmaceuticals-plc-announces-appointment-of-medical-director/
Hemogenyx Pharmaceuticals PLC Announces Appointment of Medical Director | BioSpace Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Koen van Besien as Medical Director.
07/13/2022
Hemogenyx Pharmaceuticals is hiring Cell Therapy Manufacturing Associates.
10/28/2021
Hemogenyx Pharmaceuticals PLC Announces Lease of New York Mink Building Custom Laboratory
https://www.wsj.com/articles/hemogenyx-pharmaceuticals-plc-announces-lease-of-new-york-mink-building-custom-laboratory-01634537146?tesla=y
Hemogenyx Pharmaceuticals PLC Announces Lease of New York Mink Building Custom Laboratory The Wall Street Journal news department was not involved in the creation of this content. PRESS RELEASE Hemogenyx Pharmaceuticals PLC Announces Lease of New York Mink Building Custom Laboratory October 18, 2021 LONDON, UK / ACCESSWIRE / October 18, 2021 / Hemogenyx Pharmaceuticals has signed a lease...
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the "Agreement") with the global biopharmaceutical company Eli Lilly and Company ("Lilly"). Under this Agreement, Lilly grants the Company an exclusive worldwide licence to certain intellectual property developed by Lilly ("IP") related to a CDX bispecific antibody ("CDX" or the "Licensed Product") for all uses, including the treatment of acute myeloid leukemia ("AML") and other blood cancers.
https://www.biospace.com/article/releases/hemogenyx-pharmaceuticals-announces-cdx-licence-agreement/
Hemogenyx Pharmaceuticals Announces CDX Licence Agreement | BioSpace Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement with the global biopharmaceutical company Eli Lilly and Company.
09/04/2021
We are pleased to announce that a further patent application entitled MONOCLONAL ANTIBODIES TO HUMAN FLT3/FLK2 RECEPTOR PROTEIN has been approved and issued by the United States Patent and Trademark Office.
“…The issue of this patent is of considerable significance for the Company because it protects the IP for both CDX and HEMO-CART-T product candidates…”
https://www.londonstockexchange.com/news-article/HEMO/u-s-approval-of-monoclonal-antibody-patent/15119941
U.S. Approval of Monoclonal Antibody Patent - 07:00:08 02 Sep 2021 - HEMO News article | London Stock Exchange U.S. Approval of Monoclonal Antibody Patent 07:00:08 02 Sep 2021 - HEMOGENYX PHARMACEUTICALS PLC - News article - Regulatory News Service
06/03/2021
We are pleased to announce that a patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS IN A PATIENT USING BI-SPECIFIC ANTIBODIES has been approved and issued by the United States Patent and Trademark Office.
https://www.londonstockexchange.com/news-article/HEMO/u-s-approval-and-issuance-of-cdx-antibody-patent/15001956
U.S. Approval and Issuance of CDX Antibody Patent - 16:11:45 02 Jun 2021 - HEMO News article | London Stock Exchange U.S. Approval and Issuance of CDX Antibody Patent 16:11:45 02 Jun 2021 - HEMOGENYX PHARMACEUTICALS PLC - News article - Regulatory News Service
Hemogenyx Pharmaceuticals is hiring Lab Manager - Company Coordinator.
02/03/2021
Draw Down Under Financing Facility Agreement
The use of the Financing Facility will enable to move its life-saving technologies forward rapidly, placing the Company in a highly competitive position in the treatment of cancer and viral diseases.
https://www.londonstockexchange.com/news-article/HEMO/draw-down-under-financing-facility-agreement/14850688
News article | London Stock Exchange News article - Regulatory News Service
Click here to claim your Sponsored Listing.
Our Story
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risk of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is used only as a last resort and its use is restricted. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases, such as leukemia and lymphoma, as well as severe autoimmune diseases, such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
HemoGenyx Pharmaceuticals PLC (LSE: HEMO) is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.
Videos (show all)
Category
Contact the business
Telephone
Website
Address
760 Parkside Avenue
New York, NY
11226
Opening Hours
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |
StemSave, Inc
526 W 26th Street, Suite 622
New York, 10001
Stem Cell Banking - bank your family's dental stem cells from their wisdom teeth & baby teeth.
Verndari, Inc.
New York
Verndari, Inc. was founded in 2015 with the goal of transforming global health through next generation vaccine development and delivery. The privately held company based in Napa, C...
Desres
120 W 45th Street, FL 39
New York, 10036
D. E. Shaw Research (DESRES) is engaged in scientific research and technological development in the field of computational biochemistry
Aruvant
151 W 42nd Street, 15th Floor
New York, 10036
Aruvant Sciences is a private company developing gene therapies for rare diseases. Our lead product
Builds Bio
380 LEXINGTON Avenue, SUITE 1505 NEW YORK, NY 10168
New York, 10168
The Premier Organization for Life Science, Innovation, Design, and Real Estate Professionals.
GeneCentrix
246 Fifth Avenue
New York, 10001
At GeneCentrix, we want your approval. Our novel online platform, Historeceptomics, helps you discov
Regenlabusa Customer Care
140 58th Street
New York, 11220
Cell Therapy Specialists in Standardized Autologous Regenerative Medicine. FDA Cleared and Manufactured in the USA.